Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nebivolol and Endothelial Regulation of Fibrinolysis
NCT01595516Phase 4Completed
- Sponsor
- University of Colorado Boulder
- Start
- Feb 2012
- Primary completion
- Oct 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of nebivolol in hypertension (HTN) and prehypertension (3 arms), sponsored by University of Colorado Boulder. Primary endpoints: Heart Rate at 12 weeks, Systolic Blood Pressure at 12 weeks and 3 more. Started Feb 2012; status: completed.
02
Drugs
nebivolol
03
Conditions
hypertension (HTN)prehypertension
Beyond the preview
Go deeper on NCT01595516.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01595516.